General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. Opening Hook
Shelter Pharma closed FY26 with revenue of ₹73.13 Cr, up 44% year-on-year. Profit rose 25% to ₹9.03 Cr. By the company’s own framing, a strong year.
Then the cash flow statement walked in. Operating cash flow for FY26 came in at minus ₹12.48 Cr. Free cash flow landed at minus ₹14.07 Cr. A 44% growth year that consumed cash rather than threw it off.
Earnings per share, meanwhile, slipped from ₹6.26 to ₹5.44. Profit up, per-share earnings down — equity capital rose from ₹11.56 Cr to ₹16.61 Cr on a preference issue, so the same profit was spread over more shares.
The herbal-Ayurveda maker held its first investor call on 19 June, six decades after starting in Himmatnagar. Management spent much of it on a ₹200 Cr revenue target for FY2030. The FY26 numbers had a few things to say first.
2. At a Glance
- Revenue ₹73.13 Cr (+44%) – the top line did the heavy lifting; the cash flow statement declined the credit.
- OPM 17.39%, down from 19.89% – margins shed 250 bps while revenue was busy celebrating.
- EPS ₹5.44, down from ₹6.26 – the one number that walked backwards in a growth year.
- Operating cash flow –₹12.48 Cr – profit on the page, cash out the door.
- Working capital days 234 – the cash cycle now runs longer than three full quarters.
- Promoter holding 44.38%, down from 56.89% – management’s word for the slide is “internal structuring.”
3. Management’s Key Commentary
The CFO opened with the headline: revenue from operations “stood at 73.13 Cr, up 44% year-on-year,” management said. (The top line sprinted. The cash flow statement, ₹12.48 Cr in the red, was not informed it was a sprint.)
On the long game, the Chairman said the company is “targeting annual revenues of around INR 200.00 Cr till FY-2030.” (From ₹73 Cr, that is nearly a tripling in four years — built, by his own description, on container orders of ₹1–1.5 Cr each.)
Asked whether the target was sandbagged, management replied: “These are, I think, very actual numbers, not that conservative and not so aggressive.” (The numbers are actual. The achieving of them remains, for the moment, theoretical.)
On the promoter-stake drop, the Chairman clarified: “it was not actually a stake sale from the promoters; it was some internal structuring from our side.” (Internal structuring that moved promoter holding from 56.89% to 44.38%. Structurally.)
On the margin slide, management said the dip is “only because of the expansion mode we are in.” (Margins fell 250 bps. “Expansion” — the explanation that explains every margin, in every direction.)
Pressed on a floor, an analyst asked “It will not go below 17%, right?” — management: “We hope so, yes. Of course.” (A margin floor backed by hope and an “of course.” Both currently unaudited.)
And the most candid line of the call, on the product mix: “most of our products are low-value goods,” management said. (A rare unvarnished sentence. The ₹200 Cr target rests on shipping a very great many of them.)
4. Numbers Decoded
This is a year-end call, so the full year leads and the H2 figure sits alongside. Figures are from the reported financials, consolidated basis.
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Sales | ₹73.13 Cr | ₹50.64 Cr | +44% |
| Operating Profit | ₹12.72 Cr | ₹10.07 Cr | +26% |
| OPM % | 17.39% | 19.89% | –250 bps |
| Net Profit | ₹9.03 Cr | ₹7.24 Cr | +25% |
| EPS | ₹5.44 | ₹6.26 | –13% |
| H2 (Mar-26) Sales | ₹39.84 Cr | ₹26.60 Cr | +50% |
| H2 (Mar-26) Net Profit | ₹4.53 Cr | ₹3.70 Cr | +22% |
Sales grew 44%, and operating profit grew 26% — the gap is the margin, which gave up 250 bps. EPS is the row that stands out: profit rose, EPS fell, with the share count up after the equity went from ₹11.56 Cr to ₹16.61 Cr. The H2 operating margin was thinner still, at 16.24%. And inventory days reached 160.53, the highest in the multi-year series on the sheet — the warehouse is doing well, whatever else is.
5. Analyst Questions
Cyril: “why are we still at a 44 Cr market cap?” after 60 years in business. Management answered with the family history — limited-minded uncles, the move from Himatnagar to Ahmedabad, the last ten aggressive years. (Asked about the valuation, the room received six decades of biography.)
Darshan Chandra noted EBITDA margins fell from ~20% to ~17% and asked what comes next. Management: “more than 20%, 20%, 21%, 22% going forward.” (The margin that just fell to 17% returns to 22% — going forward, the tense that owes nothing yet.)
Vinodchandra asked for the export order-book size. Management: “we cannot give you at this stage as upfront.” (The order book stayed off the record, available later, by email.)
Urvish Kothari pressed on whether any single ₹20–25 Cr order sits in the pipeline against a ₹200 Cr goal. Management pointed to low-value goods, volume, and Africa being “vacant” for them. (A ₹200 Cr ambition, ₹1.5 Cr containers, and a continent filed under “vacant.”)
6. Guidance & Outlook
All forward numbers below are management’s, stated on the call.
Management guided to roughly ₹200 Cr of revenue by FY2030, up from FY26’s ₹73.13 Cr. The existing Himatnagar plant can run to ₹100 Cr; a second facility near Ahmedabad is planned, with capex management put at ₹12–15 Cr, funded mostly from internal accruals, with installation starting from 2027. Land for it cost about ₹2.5 Cr, from accruals.
On margins, management said they will “definitely go up by 22%, 25%” over the next two-to-three years, after the current expansion-led dip. On the cash cycle, management said terms have been cut from 120 days to 90 to a targeted 60, with a longer-term aim of about one month — against a working-capital figure of 234 days on the books today.
Exports, management said, were around ₹6 Cr in FY26 (up 164%), with more than ₹5 Cr already booked in the first quarter of FY27. The nutraceutical push is positioned as the high-margin lever. The assumptions worth poking: a near-tripling of revenue, a margin reversal, and a working-capital cycle shrinking eightfold — all three at once.
7. Risks & Red Flags
- Operating cash flow of –₹12.48 Cr in FY26, with free cash flow at –₹14.07 Cr. A growth year that ate cash.
- Working capital days of 234 and a cash conversion cycle of 211, with inventory days at 160.53 — the cash is parked in receivables and stock.
- Operating margin fell 250 bps for the year to 17.39%, and the H2 margin was 16.24%.
- EPS fell to ₹5.44 from ₹6.26 as equity rose from ₹11.56 Cr to ₹16.61 Cr on the preference issue.
- Promoter holding declined from 56.89% to 44.38% across recent quarters, described by management as internal structuring.
- Exports route through the Middle East during an active conflict; management said shipments and margins are unaffected.
8. Badi Badi Baatein Vadapao Khate, Will Management Walk the Talk?
This was the first investor call, so the track record lives in the numbers, not in old promises.
On revenue, the history backs the swagger: sales ran ₹36.15 Cr, ₹39.93 Cr, ₹50.64 Cr, ₹73.13 Cr across FY23–FY26. Top-line ambition has, so far, shown up in the figures.
On margins, the history runs the other way. Operating margin went 22.54% (FY23), 22.01%, 19.89%, 17.39% (FY26) — a steady four-year decline, against management’s pledge that it will return to 22–25%. The promised direction and the realised direction have not met recently.
On the cash cycle, working-capital days went 121, 212, 182, 234 — also trending away from the “reduce to one month” commitment.
One number to reconcile: on the call management quoted ROCE of 26.04%, while the reported data sheet shows 20.4%. Same metric, two figures — worth keeping the one and watching which the next set of accounts validates.
9. EduInvesting Take
The facts on the strong side: FY26 revenue grew 44% to ₹73.13 Cr, the balance sheet carries just ₹0.80 Cr of debt, exports rose 164% off a small base, the current ratio is 7.86, and there is no pledge. The market pays 5.58x earnings against an industry P/E of 34.0, with EV/EBITDA at 3.94.
The facts on the other side: operating cash flow was –₹12.48 Cr, the working-capital cycle stretched to 234 days, the operating margin compressed 250 bps, EPS fell despite higher profit, and promoter holding dropped from 56.89% to 44.38%. The ₹37 Cr-odd of advances on the balance sheet, described as raw-material advances, is large relative to the business.
What to watch next quarter, on the company’s own metrics: whether the operating margin moves back toward management’s stated 22%; whether working-capital days fall from 234 toward the 60-day plan; whether the advances convert back into cash; how the ₹12–15 Cr second-plant capex tracks; the export run-rate after management’s ₹5 Cr first-quarter figure; and the scale-up of the high-margin nutraceutical range. Both columns, set side by side.
10. Conclusion
Shelter Pharma grew revenue 44% and spent ₹12.48 Cr of operating cash doing it. The ₹200 Cr ambition for 2030 is printed in full; the cash to fund it is, for now, leaving the building faster than it arrives — and the margin that’s meant to reverse has spent four straight years going the other way.
Written by EduInvesting Team
Sources: Shelter Pharma Ltd H2 & FY2026 Earnings Conference Call transcript (19 June 2026); H2 & FY2026 Investor Presentation; BSE filings and reported financials.